AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 22495117
Drug: 1.9 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.9 µg HA + AS03B (5.93 mg α‐tocopherol) vaccine (6 mo‐9 y)
Trial: 22495117
Drug: 3.75 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.75 µg HA + AS03A (11.86 mg α‐tocopherol) vaccine (10‐17 y)
Trial: 15658946
Drug: Therapeutic exercise
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic exercise and manipulative therapy
Trial: 7906279
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg SDZ CO 611
Trial: 7906279
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg SDZ CO 611
Trial: 7906279
Drug: 10 mg/day
RxNorm normalized name: Adlarity 10 MG/Day Weekly Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/day SDZ CO 611
Trial: 236209
Drug: 0.1 N
RxNorm normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.1 N NaHCO3 (alkaline solution)
Trial: 31408377
Drug: Antidiabetic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidiabetic treatment with glyburide, metformin, or pioglitazone
Trial: 25487313
Drug: OSAS patients
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OSAS patients before CPAP treatment
Trial: 24056618
Drug: Alemtuzumab induction
RxNorm normalized name: Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Alemtuzumab induction followed by tacrolimus monotherapy
Trial: 21401538
Drug: Dexamethasone 8
RxNorm normalized name: dexamethasone 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 8 mg + Ondansetron 4 mg
Trial: 19921359
Drug: Group B+Mor+Mg
RxNorm normalized name: meningococcal group B vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B+Mor+Mg (20 ml 0.25% bupivacaine, morphine 2 mg, magnesium 150 mg)
Trial: 19921359
Drug: Group B+Mor
RxNorm normalized name: meningococcal group B vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B+Mor (20 ml 0.25% bupivacaine, morphine 2 mg)
Trial: 19921359
Drug: Group B+Mg
RxNorm normalized name: meningococcal group B vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B+Mg (20 ml 0.25% bupivacaine, magnesium 150 mg)
Trial: 19921359
Drug: Group B
RxNorm normalized name: Blood group B IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B (20 ml 0.25% bupivacaine)
Trial: 10992996
Drug: Pharmacological lipid
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacological lipid therapy
Trial: 10992996
Drug: Standard lipid
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard lipid therapy in secondary prevention
Trial: 10992996
Drug: Primary prevention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primary prevention lipid therapy
Trial: 9347245
Drug: Troglitazone (TR),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Troglitazone (TR), 200 mg once daily
Trial: 8185689
Drug: Minocycline (maximal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minocycline (maximal oral daily dose 200 mg)
Trial: 29377462
Drug: selonsertib (SEL)
RxNorm normalized name: Selonsertib
DrugBank: Selonsertib (DB14916)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: selonsertib (SEL) 6 mg or 18 mg orally QD
Trial: 28826616
Drug: Lenalidomide (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenalidomide (10 mg/day for 3 months, then escalated to 15 mg/day)
Trial: 21585060
Drug: Medication (Rupixiao)
RxNorm normalized name: Medicated Shampoo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication (Rupixiao)
Trial: 19364999
Drug: Physical activity
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical activity advice and prescription by physicians (intervention group)
Trial: 16937497
Drug: Empirical prokinetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empirical prokinetic treatment with cisapride
Trial: 28002709
Drug: Amoxicillin‐clavulanate for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin‐clavulanate for 5 days
Trial: 28002709
Drug: Amoxicillin‐clavulanate for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin‐clavulanate for 10 days
Trial: 18691579
Drug: Endoluminal image
RxNorm normalized name: triclosan
DrugBank: Triclosan (DB08604)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Endoluminal image analysis using capsule technology (Pillcam)
Trial: 11029132
Drug: Alcohol gel
RxNorm normalized name: ALCOHOL 80 mL in 100 mL TOPICAL SOLUTION [80% Alcohol Gel]
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alcohol gel hand sanitizer used by students and staff when entering and leaving the classroom.
Trial: 11029132
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no alcohol gel hand sanitizer used).
Trial: 11029132
Drug: Alcohol gel
RxNorm normalized name: ALCOHOL 80 mL in 100 mL TOPICAL SOLUTION [80% Alcohol Gel]
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alcohol gel hand sanitizer used in schools with the largest teacher population (n = 246).
Trial: 8640699
Drug: Fadrozole HCL,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fadrozole HCL, 1 mg twice daily
Trial: 8640699
Drug: Megestrol acetate,
RxNorm normalized name: megestrol acetate, micronized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Megestrol acetate, 40 mg 4 times daily
Trial: 3535990
Drug: One year's
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One year's adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5‐fluorouracil
Trial: 29670330
Drug: Ginkgo biloba
RxNorm normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginkgo biloba extract (120 mg/day)
Trial: 12817758
Drug: Risedronate 5
RxNorm normalized name: risedronate 5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risedronate 5 mg daily for 3 years
Trial: 8866927
Drug: CFC-free metered-dose
RxNorm normalized name: acid red 337 free acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CFC-free metered-dose inhaler (CFC-free)
Trial: 8866927
Drug: CFC metered-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CFC metered-dose inhaler (CFC)
Trial: 1801963
Drug: Fluvoxamine maleate
RxNorm normalized name: Fluvoxamine Maleate
DrugBank: Fluvoxamine (DB00176)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluvoxamine maleate (50 mg, tablet) after overnight fast
Trial: 1801963
Drug: Fluvoxamine maleate
RxNorm normalized name: Fluvoxamine Maleate
DrugBank: Fluvoxamine (DB00176)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluvoxamine maleate (50 mg, tablet) after breakfast
Trial: 6144244
Drug: Relaxation Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Relaxation Therapy (R)
Trial: 6144244
Drug: Supportive Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supportive Therapy of Dynamic Type (ST)
Trial: 6144244
Drug: Basal Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basal Therapy (B)
Trial: 26762838
Drug: Anti-TNF agents
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-TNF agents (anti-TNF group)
Trial: 25384473
Drug: Double-spinning platelet-enriched
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double-spinning platelet-enriched gel (PRP) with leukocytes
Trial: 25384473
Drug: Single-spinning platelet-rich
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-spinning platelet-rich preparation (PRGF Endoret® Technology) without leukocytes
Trial: 25384473
Drug: Non-gel group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-gel group (control)
Trial: 16193341
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g L-carnitine
Trial: 10434221
Drug: Dolasetron mesylate
RxNorm normalized name: Dolasetron Mesylate
DrugBank: Dolasetron (DB00757)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dolasetron mesylate (12.5 mg, 25 mg, 50 mg, or 100 mg)
Trial: 7599221
Drug: Coenzyme Q10
RxNorm normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Coenzyme Q10 (100 mg daily for three months)
Trial: 2189951
Drug: Tamoxifen (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen (40 mg daily) for 2 or 5 years
Trial: 708560
Drug: Three formulations
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three formulations of etomidate
Trial: 30706508
Drug: Metronidazole (MTZ)
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metronidazole (MTZ) 500 mg
Trial: 30706508
Drug: NIC gum
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: NIC gum 2 mg
Trial: 26356396
Drug: L-lysine aescinat
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-lysine aescinat
Trial: 23256139
Drug: VA-fortified milk
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VA-fortified milk (250 mL daily providing 196 retinol equivalents/d) for 3 months
Trial: 21277984
Drug: Naloxone (0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone (0.15 mg/kg)
Trial: 28132005
Drug: Low energy
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low energy shock wave therapy plus eccentric exercises
Trial: 28132005
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment plus eccentric exercises
Trial: 23946609
Drug: Milligan‐Morgan hemorrhoidectomy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milligan‐Morgan hemorrhoidectomy with anal cushion suspension and partial internal sphincter resection
Trial: 16686958
Drug: Low-dose Cisplatin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose Cisplatin, 5-Fluorouracil and Interferon alpha with external beam radiation
Trial: 2935094
Drug: Continuous IV
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous IV insulin infusion of 2.5 U/h (Group B)
Trial: 2935094
Drug: Continuous IV
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous IV insulin infusion of 5.0 U/h (Group C)
Trial: 2935094
Drug: Continuous IV
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous IV insulin infusion of 7.5 U/h (Group D)
Trial: 2935094
Drug: Continuous IV
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous IV insulin infusion of 10.0 U/h (Group E)
Trial: 2935094
Drug: No insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No insulin given (Non-diabetic patients - NDP)
Trial: 2935094
Drug: Continuous IV
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous IV insulin infusion of 2.5 U/h in a patient with advanced chronic renal failure (CRF)
Trial: 12780979
Drug: Intravenous salbutamol
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous salbutamol (15 &micro;g/kg)
Trial: 10734512
Drug: Perfloxacin 400
RxNorm normalized name: pefloxacin
DrugBank: Pefloxacin (DB00487)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perfloxacin 400 mg bd twice a day for five days
Trial: 10734512
Drug: Ofloxacin 200
RxNorm normalized name: ofloxacin 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ofloxacin 200 mg bd twice a day for five days
Trial: 1954153
Drug: Ethanol at
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ethanol at 0.66 g EtOH/kg body weight
Trial: 6941640
Drug: alpha‐beta‐blocker (labetalol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alpha‐beta‐blocker (labetalol 300 mg b.d.)
Trial: 6941640
Drug: alpha‐beta‐blocker (propranolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alpha‐beta‐blocker (propranolol 80 mg b.d.)
Trial: 17631737
Drug: Laser therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laser therapy and stretching exercises (LSG, n=10)
Trial: 12413614
Drug: Cyclic transdermal
RxNorm normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclic transdermal 17‐beta estradiol (0.10 mg/day, Climara)
Trial: 8593018
Drug: Isepamicin 15
RxNorm normalized name: isepamicin
DrugBank: Isepamicin (DB13540)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isepamicin 15 mg/kg once daily for 10 days
Trial: 2649123
Drug: Extradural 0.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extradural 0.5% bupivacaine with additional morphine (bolus 4 mg plus 0.5 mg h‐1)
Trial: 2649123
Drug: Extradural 0.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extradural 0.5% bupivacaine without morphine
Trial: 367851
Drug: Levamisole (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levamisole (2.5 mg/kg body weight on 2 consecutive days/week for 3 months)
Trial: 29052236
Drug: Delayed therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed therapy ICD programming (Arm C)
Trial: 26458923
Drug: Adapted Physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adapted Physical Activity (APA) program (aerobic and resistance exercises) in addition to usual care (including chemotherapy at the investigator's choice)
Trial: 26458923
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care (including chemotherapy at the investigator's choice)
Trial: 19219907
Drug: Newly developed
RxNorm normalized name: petrolatum
DrugBank: Petrolatum (DB11058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Newly developed compound for the treatment of osteoarthritis and rheumatoid arthritis
Trial: 18551937
Drug: Intramuscular injection
RxNorm normalized name: rabies, intramuscular injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injection of botulinum toxin type‐A (BTX‐A)
Trial: 15588742
Drug: Intravenous magnesium
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous magnesium sulphate infusion
Trial: 9018020
Drug: tianeptine (25-50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tianeptine (25-50 mg/day)
Trial: 3007605
Drug: Captopril (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (100 mg orally)
Trial: 3007605
Drug: HOE 498
RxNorm normalized name: CASTOR OIL 3 mg in 30 mg / ROSEMARY 4.5 mg in 30 mg / TOCOPHEROL 9 mg in 30 mg TOPICAL LIQUID [HOEGOA Herbal Hair Growth OiI]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HOE 498 (10 mg orally)
Trial: 30545333
Drug: Intensive treatment
RxNorm normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive treatment of the mother including psychotherapy and pharmacotherapy (Step 1 treatment group)
Trial: 20868962
Drug: 0.03 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.03 mg/kg neostigmine
Trial: 20868962
Drug: 0.05 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05 mg/kg neostigmine
Trial: 18037627
Drug: Everolimus (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Everolimus (6 mg/day)
Trial: 2577377
Drug: Ebastine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ebastine (10 mg daily escalating to 40 mg daily)
Trial: 1103017
Drug: S‐Adenosylmethionine (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S‐Adenosylmethionine (25 mg i.m. three times daily)
Trial: 1103017
Drug: Imipramine (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipramine (25 mg i.m. three times daily)
Trial: 21320119
Drug: Levetiracetam (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levetiracetam (up to 30 mg/kg/day)
Trial: 19229821
Drug: Oral vitamin
RxNorm normalized name: vitamin A Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral vitamin D3 1,000 IU/day
Trial: 11456011
Drug: Levocabastine 0.05%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levocabastine 0.05% ophthalmic suspension
Trial: 8426198
Drug: Recent treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recent treatment protocols (H1, H2, H5)
Trial: 3304382
Drug: Calcitonin (i.v.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcitonin (i.v. 1.5 i.u. kg‐1 body mass bolus or 10 i.u. followed by infusion to overall 1.5 i.u. kg‐1 body mass dose)
Trial: 31752829
Drug: BV juice
RxNorm normalized name: tamarind juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BV juice (480 ml/day)
Trial: 31752829
Drug: Placebo (480
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (480 ml/day)
Trial: 21269547
Drug: 4 g
RxNorm normalized name: CTX4 Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 g EPH (egg-protein hydrolysate)
Trial: 21269547
Drug: 8 g
RxNorm normalized name: Theranost 68 Ga Rgd
DrugBank: NODAGA-THERANOST Ga-68 (DB16940)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 g EPH
Trial: 21269547
Drug: 12 g
RxNorm normalized name: PEG-12 GLYCERYL LAURATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 g EPH
Trial: 21269547
Drug: 4 g
RxNorm normalized name: CTX4 Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 g EPH with 2 g MP (milk protein)
Trial: 21269547
Drug: 4 g
RxNorm normalized name: CTX4 Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 g MP
Trial: 16952781
Drug: Oxypurinol 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxypurinol 600 mg/day for 1 month
Trial: 11149473
Drug: Single iv
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single iv infusion of 90 mg of pamidronate (group A)
Trial: 11149473
Drug: First infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: First infusion of 90 mg of pamidronate followed by 30 mg every 3 months (group B)
Trial: 8136741
Drug: 1 mg/kg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg/kg/day of ambisome
Trial: 3119786
Drug: Recombinant DNA‐produced
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant DNA‐produced gamma‐interferon (3, 30, 300, 1,000, or 3,000 micrograms/m2) administered intravenously over two hours
Trial: 3119786
Drug: Recombinant DNA‐produced
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant DNA‐produced gamma‐interferon (1,000 micrograms/m2) administered continuously over 24 hours
Trial: 3119786
Drug: Recombinant DNA‐produced
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant DNA‐produced gamma‐interferon (1,000 micrograms/m2) administered daily either by two or 24 hour infusion for 14 days
Trial: 29451869
Drug: Gel head
RxNorm normalized name: Head & Shoulders
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gel head pad (Control)
Trial: 27531486
Drug: Mecobalamin tablets
RxNorm normalized name: mecobalamin Oral Tablet
DrugBank: Mecobalamin (DB03614)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mecobalamin tablets and glutathione injection during chemotherapy
Trial: 27531486
Drug: Glutathione injection
DrugBank: Glutathione (DB00143)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glutathione injection only
Trial: 22430274
Drug: Sunitinib 50
RxNorm normalized name: sunitinib 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib 50 mg/d for 4 weeks followed by 2 weeks off treatment (schedule 4/2)
Trial: 22430274
Drug: Sunitinib 37.5
RxNorm normalized name: sunitinib 37.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib 37.5 mg/d on the continuous daily dosing (CDD) schedule
Trial: 17707978
Drug: Phytostanol supplementation
RxNorm normalized name: phytosterols
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phytostanol supplementation (1.6 g of free phytostanol equivalents as phytostanol ester, 2.7 g stanol esters)
Trial: 10960756
Drug: Clearfil Liner
RxNorm normalized name: linerixibat
DrugBank: Linerixibat (DB11729)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clearfil Liner Bond 2V after K-etchant (40% phosphoric acid gel) pre-conditioning
Trial: 8982778
Drug: Peptide immunotherapy
RxNorm normalized name: peptide-T
DrugBank: Peptide-T (DB19279)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peptide immunotherapy (IPC-1 and IPC-2, 250 micrograms, s.c. injections weekly for 4 weeks)
Trial: 8982778
Drug: Peptide immunotherapy
RxNorm normalized name: peptide-T
DrugBank: Peptide-T (DB19279)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peptide immunotherapy
Trial: 1451645
Drug: L-carnitine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-carnitine (30 mg/kg)
Trial: 6431573
Drug: 0.5-mg oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5-mg oral dose of brotizolam
Trial: 30887937
Drug: Green banana
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Green banana biomass (40 g) (RS: approximately 4·5 g)
Trial: 30086659
Drug: Group-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group-based cognitive behavioral therapy (CBT) stress management program
Trial: 26968269
Drug: Nebulised salbutamol
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nebulised salbutamol alone (0.03 ml/kg/dose)